Gene therapy's promise is being strangled by broken economics and political neglect. Per-patient costs can run into seven figures, and companies like Prime Medicine are already halting work on successful treatments because the business model doesn't hold up. Only a publicly funded health system treating gene therapy like dialysis or transplants — a collective service, not a market commodity — can turn lab breakthroughs into medicine for everyone.